Change in muscle volume after steroid therapy in patients with myositis assessed using cross-sectional computed tomography

Table 1 Profiles of the patients in the myositis group

Patient	Age (years)	Sex	Diagnosis	Max glucocorticoid (mg/day)^a	Duration between the start of treatment and second CT (months)^b	Dose of glucocorticoid at second CT (mg/day)	Cumulative doses of glucocorticoid (g)^c	MMT (before → after)^d	Serum level of CK (U/L) (before → after)	Daily intake of protein in hospital (g/day)
1	26	M	DM	mPSL → PSL: 60	3	PSL: 25	PSL: 4.3	3+/3+ → 4+/4	102 → 21	80.0
2	58	F	DM	PSL: 40	2	PSL: 20	PSL: 1.7	4−/4- → 4/4-	500 → 17	54.0
3	74	F	DM	PSL: 45	2.5	PSL: 18	PSL: 2.3	4−/3+ → 4/4	3677 → 55	67.5
4	70	M	DM	mPSL → sPSL: 100	4	PSL: 22.5	PSL: 6.1	3−/3- → 4+/4+	5149 → 22	65.0
5	70	M	DM	PSL: 60	7.5	PSL: 12	PSL: 6.0	4+/4 → 5/5	1119 → 122	75.0
6	15	F	MCTD	PSL: 50	1	PSL: 50	PSL: 1.4	5−/5 → 5/5	876 → 219	70.0
7	69	F	MCTD	PSL: 40	3	PSL: 20	PSL: 2.7	4/4- → 5−/5-	2210 → 69	65.0

M male, F female, DM dermatomyositis, MCTD mixed connective tissue disease, PSL prednisolone, mPSL methylprednisolone, sPSL soluble prednisolone, MMT manual muscle test, creatine kinase
^aInitial mPSL dose was 1 g × 3 d
^bThe first CTs were performed within six weeks before the initial steroid therapy
^cSteroid taken using steroid pulse was excluded from cumulative doses of glucocorticoid
^dMuscle strength of the bilateral iliopsoas muscle was evaluated using MMT before and after steroid therapy

ISSN: 1471-2474